Business
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical
About this update from Catalyst Pharmaceuticals, Inc.
[{"type":"text","content":"CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (\"Catalyst\") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company will showcase real‑world findings in Duchenne muscular dystrophy (DMD) through multiple poster presentations at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. Catalyst will also sponsor a vamorolone-focused MDA Industry Forum with Santhera Pharmaceuticals. “The MDA meeting is a key opportunity to highlight the expanding real‑world evidence shaping care for the Duchenne community,” said Will Andrews, MD, Chief Medical Officer of Catalyst. “Through our poster presentations and our sponsored symposium on long‑term evidence generation, we’re contributing clinical insights that help clarify AGAMREE®’s profile and its role in patient care. Our commitment is to advance rigorous, meaningful research that moves the field forward for patients and their families.” The poster presentations will focus on real-world analysis of vamorolone in patients living with DMD: Poster Presentations: Abstract Title: Real-world analysis of concomitant cardiac medication use with the novel corticosteroid vamorolone in patients with Duchenne muscular dystrophy (DMD) Authors: Linda Cripe, MD, Nationwide Children's Hospital, Steven Woods, PharmD, Catalyst, Katherine Habkouk, PharmD, AnovoRx Specialty Pharmacy, Regina Grebla, PhD, Northeast Epi, LLCSession Name: Poster SessionTopic: Clinical ManagementPoster Number: 74 SDate of Presentation: Sunday, March 8, 2026, 6:00 PM–8:00 PM ET Abstract Title: Association Between Glucocorticoid Treatment Duration and Health Care Resource Utilization in Duchenne Muscular Dystrophy: A Real-World Analysis.Authors: Steven Woods, PharmD, Catalyst Pharmaceuticals, Bridget McGowan, MD, Ann and Robert H. Lurie Children's Hospital of Chicago, Ashley Martin, PhD, BluePath Solutions, Alexa Gordon, MS, BluePath Solutions, Sana Mirza, MPH, BluePath Solutions, Paula Alvarez, MBA, MS, Rph, Critical Intelligence Consulting Session Name: Poster SessionTopic: OtherPoster Number: 75 SDate of Presentation: Sunday, March 8, 2026, 6:00 PM–8:00 PM ET Abstract Title: Glucocorticoid Use and Delayed Res...